Natriuretic Peptides in Patients with Renal Failure

Markers in Cardiology: A Case-Oriented Approach

Volumn , Issue , 2008, Pages 170-180

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Amlodipine; Dialysis; Hydralazine; Orthopnea; Renal failure

Indexed keywords

EID: 84889771520     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691984.ch15     Document Type: Chapter

References (28)

1. McCullough PA, Kuncheria J, Mathur VS. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S3-S12.
2. Totsune K, Takahashi K, Satoh F et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996;63:141-147.
3. Wegner M, Ganten D, Stasch JP. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats. Hypertens Res 1996;19:229-238.
4. Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui K. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 1999;370:307-312.
5. Ng LL, Loke IW, Davies JE et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J AmColl Cardiol 2005;45(7):1043-1050.
6. McCullough PA, Duc P, Omland T et al. Breathing not properly multinational study investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. AmJ Kidney Dis 2003;41(3):571-579.
7. Safley DM, Awad A, Sullivan RA et al. Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis 2005;12(1):117-124.
8. Dumler F, McCullough PA. Optimal dialysis for the end-stage renal disease patient with cardiovascular disease. Adv Chronic Kidney Dis 2004;11(3):261-273.
9. Zoccali C et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12(7):1508-1515.
10. Naganuma T et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002;22(5-6):437-444.
11. Goto T et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002;92(3):610-615.
12. Ishizaka Y et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis 1994;24(3):461-472.
13. Corboy JC et al. Plasma natriuretic peptides and cardiac volume during acute changes in intravascular volume in haemodialysis patients. Clin Sci (Lond) 1994;87(6):679-684.
14. Haug C et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994;26(5):246-249.
15. Totsune K, Takahashi K, Murakami O, Satoh F, Sone M, Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci (Lond) 1994;87(3):319-322. Erratum in: Clin Sci (Colch) 1994;87(6):following xxv.
16. Ishizaka Y, Yamamoto Y, Tanaka M et al. Molecular forms of human brain natriuretic peptide (BNP) in plasma of patients on hemodialysis (HD). Clin Nephrol 1995;43(4):237-242.
17. Takahashi M et al. Plasma concentrations of natriuretic peptides in patients on hemodialysis. Res Commun Mol Pathol Pharmacol 1996;92(1):19-30.
18. Nitta K et al. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 1998;18(5):411-415.
19. Osajima A et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 2001;21(2):112-129.
20. Nishikimi T et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001;37(6):1201-1208.
21. Clerico A et al. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001;24(1):24-30.
22. Uetake S, Takahashi M, Tamano K, Honda T, Kobayashi T, Horinaka S. Clinical significance of plasma atrial and brain natriuretic peptide levels during hemodialysis in hemodialysis patients with old myocardial infarction. J Cardiol 2001;38(2):61-71.
23. Wu AH, Omland T, Wold Knudsen C et al., for The Breathing Not Properly Multinational Study Investigators. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) multinational study. Am J Hematol 2005;80(3):174-180.
24. Anwaruddin S, Lloyd-Jones DM, Baggish A et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47(1):91-97.
25. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006;103(4):c162-c172.
26. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005;6(suppl 3):4-12.
27. Daniels LB, Clopton P, Bhalla V et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151(5):1006-1012.
28. McCullough PA, Mueller C, Yancy CW, Jr. Overview of B-type natriuretic peptide as a blood test. Congest Heart Fail 2006;12(2):99-102.